Liquidia Corporation (LQDA)
$33.94+26.59%Close
SELLCRISIS · day 11
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV26.9%–238.7%
- Market cap
- $3.0B
- Beta
- 0.54
- P/E (TTM)
- 21.63
- IV-%ile
- 71
- IV ATM
- 123.7%
- Short % float
- 20.28%
- Days to cover
- 3.8
- SI change
- +2.1%
- 1W
- +27.21%
- 1M
- -48.36%
- vs SPY 1W
- +27.35%
- vs SPY 1M
- -50.86%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 32
- VALUE
- 23
- GROWTH
- 61
- GARP
- 13
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC89.8%
REV YoY-
ROE149.6%
EPS YoY-
ROA26.6%
GROSS92
OP37
NET31
[VALUATION]
P/E TTM21.63
P/E FWD18.25
SECTOR PE20.48
INDUSTRY PE100.15
P/B15.46
P/FCF-
EV/EBITDA16.10
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E66.09
ALTMAN Z-
CURR RATIO2.31
ND/EBITDA-
BETA0.54
Company news
FAQ
- What is LOPJLB’s current signal on LQDA?
- LOPJLB’s latest quantitative signal on Liquidia Corporation (LQDA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LQDA in?
- Liquidia Corporation (LQDA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Liquidia Corporation (LQDA) do?
- Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hyper…